Journal
HUMAN MUTATION
Volume 40, Issue 7, Pages 908-925Publisher
WILEY
DOI: 10.1002/humu.23731
Keywords
congenital disorders of glycosylation; glycoside; nucleotide sugar transporter; UDP-galactose
Categories
Funding
- National Institutes of Health (NIH) [R01DK099551]
- Rocket Fund
- National Science Center [2016/21/B/NZ5/00144]
- NIH (NINDS) [5R01NS050375, 1R01NS058721]
Ask authors/readers for more resources
Pathogenic de novo variants in the X-linked gene SLC35A2 encoding the major Golgi-localized UDP-galactose transporter required for proper protein and lipid glycosylation cause a rare type of congenital disorder of glycosylation known as SLC35A2-congenital disorders of glycosylation (CDG; formerly CDG-IIm). To date, 29 unique de novo variants from 32 unrelated individuals have been described in the literature. The majority of affected individuals are primarily characterized by varying degrees of neurological impairments with or without skeletal abnormalities. Surprisingly, most affected individuals do not show abnormalities in serum transferrin N-glycosylation, a common biomarker for most types of CDG. Here we present data characterizing 30 individuals and add 26 new variants, the single largest study involving SLC35A2-CDG. The great majority of these individuals had normal transferrin glycosylation. In addition, expanding the molecular and clinical spectrum of this rare disorder, we developed a robust and reliable biochemical assay to assess SLC35A2-dependent UDP-galactose transport activity in primary fibroblasts. Finally, we show that transport activity is directly correlated to the ratio of wild-type to mutant alleles in fibroblasts from affected individuals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available